メインコンテンツにスキップ

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at … Continued

サターラ、Applied Biomath社を買収:バイオシミュレーションポートフォリオを拡大し、新規治療薬の最適投与に向けた新機能を強化

両社の統合によりライフサイエンス業界最大の定量的システム薬理学(QSP)支援体制が確立され、より迅速で効果的な医薬品開発に貢献します。2023年12月14日、ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT) today announced it has acquired Applied Biomath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and … Continued

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies Princeton, NJ – November 21st, 2023 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex … Continued

サターラ が2023年第3四半期決算を報告

 Reiterates Full Year 2023 Financial Guidance PRINCETON, N.J.— November 8, 2023– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: “During the third quarter we saw customer demand stabilize across the Certara platform. We continue to see strong interest from … Continued

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors … Continued

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines. PRINCETON, NJ – September 19th,  2023 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions include those to initiate clinical trials, such as Investigational New Drug (IND) or Clinical … Continued

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 29, 2023 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Live webcasts for each of the conferences will be available on Certara’s investor relations website athttps://ir.certara.com and will be available for replay for at least 90 days thereafter. … Continued

Certara Simcyp™ Group Awarded Two New Grants from US FDA

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations PRINCETON, N.J.— 2023年8月29日– Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food and Drug Administration (FDA) to expand its … Continued

Certara Reports Second Quarter 2023 Financial Results

 Provides Update to Full Year 2023 Financial Guidance PRINCETON, N.J.— August 9, 2023– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: “During the second quarter our software business performed well, but we experienced lower growth than expected in our … Continued

Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023

PRINCETON, N.J.— 2023年7月13日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued

1 of 33
Powered by Translations.com GlobalLink OneLink Software